BioPhenoMA Inc. and Tokyo Medical University have established a collaborative research initiative to create novel biomarkers for urothelial carcinoma.Our project will be led by Dr. Yosuke Hirasawa, a distinguished lecturer at Tokyo Medical University, and our Chief Scientific Officer (CSO), Etsuro Ito, the inventor of TN-cyclon™. Their combined expertise and experience will be invaluable in ensuring the success of this endeavor.Through the examination of ultra-trace proteins present in urine, the study seeks to make significant contributions to the diagnosis and treatment of urothelial carcinoma.We are excited about the potential of this partnership and look forward to the groundbreaking advancements that will result from it.